Published in Br J Clin Pharmacol on March 01, 1991
Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol (1995) 1.28
Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clin Pharmacokinet (1995) 1.08
Debrisoquine and mephenytoin oxidation in Sinhalese: a population study. Br J Clin Pharmacol (1994) 0.91
Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol (1993) 0.87
Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol (1999) 0.84
The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study. Br J Clin Pharmacol (1993) 0.79
Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra-individual reproducibility and occurrence of adverse events. Br J Clin Pharmacol (2001) 0.76
Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. Eur J Clin Pharmacol (2007) 0.75
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther (1985) 2.69
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther (1984) 2.19
S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther (1989) 1.41
Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther (1985) 1.38
Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther (1984) 1.25
Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmacol Ther (1985) 1.12
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol (1989) 1.06
Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol (1990) 0.97
Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos (1987) 0.93
Global regulation of Staphylococcus aureus genes by Rot. J Bacteriol (2003) 3.02
Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther (1981) 2.93
Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother (1982) 2.32
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther (1984) 2.19
Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. I. A hybridoma secreting antibody against a marker specific for human B lymphocytes. Clin Exp Immunol (1980) 1.66
A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry (1999) 1.51
Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol (2000) 1.51
Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clin Pharmacol Ther (1978) 1.51
Genetic aspects of drug disposition and therapeutics. J Clin Pharmacol (1992) 1.46
Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. Equine Vet J (1997) 1.40
Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem (1975) 1.39
Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther (1985) 1.38
Detection of Borna disease virus (BDV) antibodies and BDV RNA in psychiatric patients: evidence for high sequence conservation of human blood-derived BDV RNA. J Virol (1996) 1.29
Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose. Eur J Clin Pharmacol (1982) 1.27
Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm (1980) 1.26
Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J Pharmacol Exp Ther (2002) 1.24
Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem (1995) 1.20
Scanning electron microscopic study of microcrystals implicated in human rheumatic diseases. Scan Electron Microsc (1980) 1.20
Estimating creatinine clearance in morbidity obese patients. Am J Hosp Pharm (1981) 1.17
Membrane antigens of human cells of the monocyte/macrophage lineage studied with monoclonal antibodies. Pathology (1983) 1.17
Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. IV. A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes. J Immunol (1981) 1.17
Effect of plasma protein and tissue binding on the biologic half-life of drugs. Clin Pharmacol Ther (1978) 1.16
Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. II. A hybridoma secreting antibody against an antigen expressed by human B and null lymphocytes. Clin Exp Immunol (1980) 1.11
Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res (1984) 1.11
Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther (1979) 1.08
Patent ductus arteriosus treatment in preterm infants-time to consider shunt volume? J Perinatol (2013) 1.06
Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations. Eur J Clin Pharmacol (1983) 1.05
Clinical pharmacokinetics of verapamil. Clin Pharmacokinet (1984) 1.05
CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J (2006) 1.05
Aluminium toxicokinetics: an updated minireview. Pharmacol Toxicol (2001) 1.04
Does point-of-care functional echocardiography enhance cardiovascular care in the NICU? J Perinatol (2008) 1.04
Postoperative cardiorespiratory instability following ligation of the preterm ductus arteriosus is related to early need for intervention. J Perinatol (2008) 1.03
Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest (1994) 1.02
A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry (2007) 1.00
Objectives, design and recruitment of a familial and longitudinal cohort for studying gene-environment interactions in the field of cardiovascular risk: the Stanislas cohort. Clin Chem Lab Med (1998) 1.00
Impact of a physician-staffed helicopter on a regional trauma system: a prospective, controlled, observational study. Acta Anaesthesiol Scand (2013) 1.00
Monocrystalline calcium hydrogen phosphate dihydrate in destructive arthropathies of chondrocalcinosis. Lancet (1977) 0.99
Failure of pediatric and neonatal trainees to meet Canadian Neonatal Resuscitation Program standards for neonatal intubation. J Perinatol (2009) 0.99
Factors influencing serum protein binding of lidocaine in humans. Anesth Analg (1981) 0.99
Factors affecting the milk-to-plasma drug concentration ratio in lactating women: physical interactions with protein and fat. J Pharm Sci (1987) 0.99
High sensitivity C-reactive protein: biological variations and reference limits. Clin Chem Lab Med (2000) 0.98
Anhydrous lead(II) heptanoate. Acta Crystallogr C (2001) 0.98
The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther (1996) 0.97
Age-associated stereoselective alterations in hexobarbital metabolism. Clin Pharmacol Ther (1988) 0.97
Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol (1990) 0.97
The effect of variation in the apolipoprotein B gene on plasmid lipid and apolipoprotein B levels. I. A likelihood-based approach to cladistic analysis. Ann Hum Genet (1994) 0.96
Septicemia with two distinct strains of Staphylococcus aureus and dwarf variants of both. Isr J Med Sci (1985) 0.95
An analysis of genotype effects and their interactions by using the apolipoprotein E polymorphism and longitudinal data. Am J Hum Genet (1989) 0.95
The Beck Depression Inventory and Research Diagnostic Criteria: congruence in an older population. J Consult Clin Psychol (1983) 0.95
Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos (1987) 0.93
Hybridomas secreting monoclonal antibody to Toxoplasma gondii. Aust J Exp Biol Med Sci (1981) 0.93
Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol (1993) 0.93
Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther (1982) 0.93
Performance of a diffusional clearance model for beta-lactam antimicrobial agents as influenced by extravascular protein binding and interstitial fluid kinetics. Antimicrob Agents Chemother (1985) 0.93
Active transport of nitrofurantoin into human milk. Pharmacotherapy (2001) 0.93
Targeted neonatal echocardiography (TnECHO) service in a Canadian neonatal intensive care unit: a 4-year experience. J Perinatol (2013) 0.93
Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther (1992) 0.92
Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol (1983) 0.92
Hepatic cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/p75) knockout mice after endotoxin administration. J Pharmacol Exp Ther (1999) 0.92
Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency. Antimicrob Agents Chemother (1989) 0.91
Tissue binding of drugs. J Pharm Sci (1977) 0.91
Single-dose ceftriaxone kinetics in liver insufficiency. Clin Pharmacol Ther (1984) 0.91
Maturation of human B lymphocytes--studies with a panel of monoclonal antibodies against membrane antigens. Clin Exp Immunol (1983) 0.91
Entry, half-life, and desferrioxamine-accelerated clearance of brain aluminum after a single (26)Al exposure. Toxicol Sci (2001) 0.90
Bioavailability of syrup and tablet formulations of cefetamet pivoxil. Antimicrob Agents Chemother (1993) 0.90
Active transport of cimetidine into human milk. Clin Pharmacol Ther (1995) 0.90
Identification of CYP2C23 expressed in rat kidney as an arachidonic acid epoxygenase. J Pharmacol Exp Ther (1993) 0.90
Cognitive dysfunction after cardiovascular surgery. Minerva Anestesiol (2009) 0.90
Aluminum bioavailability from drinking water is very low and is not appreciably influenced by stomach contents or water hardness. Toxicology (2001) 0.89
Identification of microcrystals in synovial fluids by combined scanning electron microscopy and x-ray diffraction : application to triclinic calcium pyrophosphate dihydrate. Biomedicine (1977) 0.89
High-fidelity simulator technology may not be superior to traditional low-fidelity equipment for neonatal resuscitation training. J Perinatol (2011) 0.89
Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur J Clin Pharmacol (1978) 0.89
Pharmacokinetics of theophylline in young and elderly subjects. Gerontology (1982) 0.89
Theophylline clearance: effect of marked obesity. Clin Pharmacol Ther (1980) 0.89
Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metab Dispos (1999) 0.89
Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol (1984) 0.88
Influence of age on theophylline clearance in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet (1982) 0.88
Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr (1984) 0.88
Delivery room resuscitation of preterm infants in Canada: current practice and views of neonatologists at level III centers. J Perinatol (2011) 0.88
A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide. Biochem J (1989) 0.88
Single-dose ceftriaxone kinetics in functionally anephric patients. Clin Pharmacol Ther (1983) 0.88
Antipyrine as a dialyzable reference to correct differences in efficiency among and within sampling devices during in vivo microdialysis. J Pharmacol Toxicol Methods (1992) 0.88
Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes. Drug Metab Dispos (1992) 0.87
Soluble transferrin receptor (sTfR): biological variations and reference limits. Clin Chem Lab Med (2001) 0.87
Head injury and cytochrome P-450 enzymes. Differential effect on mRNA and protein expression in the Fischer-344 rat. Drug Metab Dispos (1994) 0.86
Cimetidine-induced decrease in lidocaine metabolism. Am Heart J (1984) 0.86
Possible effect of lactational period on the milk-to-plasma drug concentration ratio in lactating women: results of an in vitro evaluation. J Pharm Sci (1989) 0.86
Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin Chim Acta (1981) 0.86
Frequencies of five genetic polymorphisms in coronarographed patients and effects on lipid levels in a supposedly healthy population. Clin Genet (1996) 0.86
In vivo evaluation in the lactating rabbit of a model for xenobiotic distribution into breast milk. J Pharmacol Exp Ther (1988) 0.86
Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. Clin Nephrol (2002) 0.86
Purification of the phospholipase D of Corynebacterium pseudotuberculosis by recycling isoelectric focusing. Am J Vet Res (1989) 0.86
Early discontinuation of intravenous prostaglandin E1 after balloon atrial septostomy is associated with an increased risk of rebound hypoxemia. J Perinatol (2008) 0.86
Fraction unbound in interstitial fluid. J Pharm Sci (1983) 0.85